WAIT TILL DAY'S END
The cronology of events was not what we expected today, however I will be anxious to see how the day plays out after financials are out and the shorting calms down. The AVRT program appears to be well thought out with more bang for the buck, patients are being lined up and at $1500 a test, we are first to market, there is potential for revenue given that patients are in queue, marketing money is there and we have a new partner that Tripp has chosen carefully. Science and all the other variables are the same as yesterday when we were at $1.57. Lots of bashers here today because its a happy day for them - but lets see where we are after the chips fall. Those thinking its best to sell now at $1.13 can simply move on but I'm not selling a single share.